Squarepoint affiliates report ~8.3% stakes in Cartesian Therapeutics
Cartesian Therapeutics, Inc. disclosure: multiple Squarepoint entities report beneficial ownership stakes in Common Stock totaling between 30,949 and 2,209,601 shares per entity as filed on 03/09/2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Cartesian Therapeutics, Inc. disclosure: multiple Squarepoint entities report beneficial ownership stakes in Common Stock totaling between 30,949 and 2,209,601 shares per entity as filed on 03/09/2026.
The filing lists Squarepoint Ops LLC, Squarepoint Capital LLP, Squarepoint Operations Private Limited, and Squarepoint (DIFC) Ltd each holding 2,209,601 shares (reported 8.34% of the class), Squarepoint Master Fund Limited holding 2,178,652 shares (8.22%), and Squarepoint Core Master Fund Limited holding 30,949 shares (0.12%).
Insights
Squarepoint's institutional positions cross multiple affiliates with shared voting and dispositive power.
The filing attributes shared voting and shared dispositive power to each Squarepoint affiliate: 2,209,601 shares for four affiliates, 2,178,652 for one, and 30,949 for the smaller affiliate, with percentages shown per entity.
These entries indicate coordinated holdings reported by separate legal entities; subsequent filings would clarify any consolidation of beneficial ownership or changes in voting alignment.
Positions represent single‑entity percentages near 8.3%, implying sizable passive stakes by funds.
The reported percentages are 8.34% per four affiliates and 8.22% for the master fund, with one small affiliate at 0.12%. Each entry ties a share count to a clear percentage in the filing.
These holdings may affect float calculations; further filings could reveal aggregated exposure or any Section 13(d) triggers if ownership is consolidated.
AI-generated analysis. How Rhea-AI works. Not financial advice.